An expert group is working on a list of cancer drugs that will be subject to a new 30% trade margin cap. This initiative aims to significantly lower the retail prices of both branded and generic cancer medicines. The expected outcome is a potential price drop of up to 70% for some anti-cancer drugs, translating into substantial savings for patients. This move is part of a broader government effort to make essential medicines more affordable. For more detailed information, refer to the original publication.
Read the original article